Back to Search
Start Over
Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine
- Source :
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p769-769, 1p
- Publication Year :
- 2023
-
Abstract
- Background.Maintaining remission in AML after intensive chemotherapy continues to be a challenge, specifically in patients with measurable residual disease (MRD+). Immunotherapy could be an effective way to induce durable disease control for patients in remission. This phase 2 study used an allogenic leukemia-derived dendritic cell vaccine to induce an effective anti-leukemic response to control or eradicated MRD, leading to durable disease control. (ADVANCE-II, Clintrials.gov: NCT03697707).
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 142
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs64589254
- Full Text :
- https://doi.org/10.1182/blood-2023-185532